Jubilant DraxImage Signs Term Sheet with Cyclopharm for Exclusive License to Market Technegas in the United States
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150913005094/en/
DraxImage President Martyn Coombs stated, “Jubilant DraxImage is excited about this opportunity to participate with Cyclopharm in the clinical development and potential US market introduction of this innovative nuclear medicine product. The execution of this Term Sheet demonstrates DraxImage’s commitment to invest in and grow the sustainability of ventilation/perfusion imaging in the US and our continued passion to bring innovative products that enable physicians to deliver high quality diagnostics to their patients”.
Cyclopharm CEO James McBrayer stated that “Cyclopharm is thrilled with the opportunities this transaction represents. DraxImage is the USA market leader for nuclear medicine lung imaging. We are confident that the synergies that exist between our organizations will ensure faster acceptance of our proprietary technology.”
About Jubilant DraxImage
Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences, develops, manufactures and commercializes radiopharmaceuticals used for the diagnosis and treatment of disease. The company is dedicated to nuclear medicine and serves customers and through them patients, globally, with high quality and reliable products and services. The company is the market leader in North America for I-131 products (diagnosis and treatment of thyroid disorder and cancer), MAA (lung perfusion imaging), DTPA (renal imaging) and MDP (bone imaging), and also markets other products such as Sestamibi (myocardial perfusion imaging) and Gluceptate (brain and renal imaging). The company has a strong development pipeline of new products, notably a Rubidium-82 Generator (PET Cardiology).
About Cyclopharm Limited
Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas (for lung imaging).
About Technegas
The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700oC. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).
View source version on businesswire.com: http://www.businesswire.com/news/home/20150913005094/en/
Website: http://www.draximage.com
Contact
Jubilant DraxImage
Ms Suzanne Bissonnette
Director, Marketing
1-888-633-5343
sbissonnette@jdi.jubl.com
www.draximage.com
Cyclopharm Limited
Mr James McBrayer
CEO, Managing Director & Company Secretary
+61 295 41 04 11
jmcbrayer@cyclopharm.com.au
www.cyclopharm.com
This news is a press release provided by Jubilant DraxImage Inc. and Cyclopharm Limited.
